Replies to post #1809 on Idenix Pharmaceuticals (IDIX)

[go seek]

DD called it "bureaucratic inertia"
AASLD will come in time... 'specially if head to head shows Tyzeka equal or superior

One thing we know for sure is the HBV market is not shrinking...
rather is experiencing exponential growth

w/ $200M in Tyzeka/Sebivo annual sales... (not a pipe dream IMO)
IDIX is 5-10 times its current P/S valuation